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INTRODUCTION
Breast cancer is the most common malignancy among women 
globally. In the United States, more than 200000 new cases of 
invasive breast cancer and more than 60000 new cases of in 
situ breast cancer were expected among US women in 2013.1,2 
Approximately 40000 US breast cancer patients were expected 
to die in 2013; however, breast cancer death rates decreased by 
34% from 1990 to 2010.2 Similarly, the incidence rate of breast 
cancer is continuously increasing in Korea, and it is the second 
most common cancer among Korean women.3 The Korean Br-
east Cancer Society reported that the number of newly-diag-
nosed breast cancer patients was more than 16000 and that the 
crude age-specific incidence rate of women aged 40 to 49 years 
was the highest, with approximately 148 cases per 100000 
women in 2010.4 The 5-year relative survival rate of female br-
east cancer patients diagnosed in 2006–2010 improved from 
78.0% to 91.0% compared to those diagnosed in 1993–1995.3
Increasing survival rates in breast cancer patients are attrib-
uted to both early detection of malignancies and improvements 
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in treatment.2,3 With increasing incidence and survival rates of 
such malignancies, the number of cancer survivors continues 
to increase in Korea. Although many cancer survivors return to 
normal daily activities after the completion of primary treat-
ment, the cancer itself and related treatments may also result in 
a wide range of chronic, long-term physical and psychological 
problems.5 Of these issues, second or multiple primary cancers 
(MPCs) are both disastrous and lethal in this patient popula-
tion. An increased risk of MPCs in cancer survivors compared 
to the general population has been associated with complex 
factors including genetic predisposition, host factors, environ-
mental determinants, gene-environment interactions, shared 
lifestyle factors (e.g., tobacco use or excessive alcohol intake), 
and the late effects of cancer treatments (e.g., cytotoxic, radia-
tion, or hormonal therapies).6
MPCs are generally defined according to the criteria of War-
ren and Gates7 as follows: 1) each tumor must have clear evid-
ence of malignancy on histologic examination, 2) each tumor 
must be geographically separate and distinct, and 3) the pos-
sibility of a metastatic lesion having spread from a prior can-
cer must be excluded. Recent rules for classifying MPCs have 
been modified based on the cancer site of origin, date of diag-
nosis, histology, tumor behavior (i.e., in situ versus invasive), 
and laterality of the paired organ.8 International coding rules for 
MPCs are more restrictive, and MPCs occurring at the same 
site or on different sides of a paired organ are usually consider-
ed to be first primary unless the two tumors are of completely 
different histology.8,9
Trends of cancer incidence and mortality vary by age and be-
tween nations. Considering that the crude age-specific inci-
dence rates of Korean breast cancer patients are different from 
those of Western countries,4 risks for and survival of MPCs sh-
ould be clarified in Korean breast cancer patients. However, 
limited information is available on this subject.5,10 This study 
aims to investigate patterns of MPCs in Korean breast cancer 
patients treated at a single institution and to examine the char-
acteristics and survival rates of these patients after diagnosis ac-
cording to the presence or absence of MPCs.
MATERIALS AND METHODS
A total of 8204 patients with locoregional breast cancer were 
retrospectively selected from the Severance Hospital breast 
cancer registry. The Severance Hospital registry prospectively 
records clinicopathological information including past histo-
ries of cancer and details on survival outcomes. Additional in-
formation for MPCs was obtained from the Yonsei Cancer 
Registry of Yonsei University Health System in Seoul, Korea. All 
patients underwent surgery for primary breast cancer between 
January 1990 and December 2012. Patients with stage IV dis-
ease at the time of diagnosis were excluded. In this study, pa-
tients with bilateral breast cancer at initial diagnosis or during 
follow-up periods were not considered to have MPCs. In cases 
of simultaneous bilateral breast cancer, the side with the more 
advanced stage was selected, and in cases of metachronous bi-
lateral breast cancers, the initial index tumor was considered 
for analysis.
In this study, the criteria of Warren and Gates7 were used to 
define MPCs. Synchronous MPCs were defined as a tumor di-
agnosed simultaneously with breast cancer or within a time in-
terval of 6 months. Metachronous MPCs were considered to be 
a tumor detected more than 6 months before or after diagnosis 
of breast cancer. For survival analysis according to follow-up 
time period and time of diagnosis of MPCs, the patient cohort 
was subdivided into two groups as follows: patients with or 
without MPCs at a time point within a follow-up duration of 5 
years or less (time period ≤5 years, n=8204) and those with or 
without MPCs among patients with a follow-up duration of 
more than 5 years (time period >5 years, n=3745). Therefore, 
patients who died after >5 years of being diagnosed with breast 
cancer were considered to be alive at ≤5 years. Similarly, pa-
tients diagnosed with metachronous MPCs at >5 years after 
being diagnosed with breast cancer were placed in the breast-
cancer-alone group with a time period ≤5 years. Patients who 
died or were lost to follow-up within 5 years of being diagnosed 
with breast cancer were excluded from the analysis of the time 
period >5 years.
Clinical follow-up included a patient interview, physical ex-
amination, laboratory tests, and breast imaging every 6–12 
months. If necessary, an abdominopelvic ultrasound, bone 
scan, computed tomography (CT) scan, or fluorin-18 fluorode-
oxyglucose positron emission tomography/CT scan was per-
formed. Tumor-node-metastasis (TNM) staging was based on 
the 6th American Joint Committee on Cancer criteria.11 Tumors 
with ≥1% nuclear-stained cells were considered positive for es-
trogen receptor (ER) and progesterone receptor (PR) accord-
ing to the American Society of Clinical Oncology/College of 
American Pathologists guidelines.12 Human epidermal growth 
factor receptor 2 (HER2) staining was not available during the 
early 1990s, and HER2 3+ scores were considered positive.
Differences between groups were evaluated by the chi-squ-
are test. Continuous variables were compared using the inde-
pendent two-sample t-test. Overall survival (OS) was calculated 
from the date of surgery for breast cancer to the date of the last 
follow-up or death from any cause. The date of the last follow-
up was used as censored data in this analysis. Survival curves 
were plotted using the Kaplan-Meier method, and group differ-
ences in survival curve were investigated by the log-rank test. 
A Cox proportional hazard model was used to identify vari-
ables that were independently associated with OS. All statisti-
cal tests were two-sided and a p-value<0.05 was considered 
statistically significant. Categorical variables were expressed 
as a frequency and percentage. SPSS version 20.0 (IBM Inc., Ar-
monk, NY, USA) was used for all statistical analyses.
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RESULTS
Of the 8204 breast cancer patients with stage 0 to III disease, 
858 patients (10.5%) had MPCs: 268 patients (31.2%) had meta-
chronous MPCs alone ≥6 months before diagnosis of breast 
cancer, 180 patients (21.0%) had synchronous MPCs alone, 370 
patients (43.1%) had metachronous MPCs alone ≥6 months 
after diagnosis of breast cancer, 10 patients (1.2%) had both 
metachronous MPCs ≥6 months before the diagnosis of breast 
cancer and synchronous MPCs, 14 patients (1.6%) had both 
synchronous and metachronous MPCs ≥6 months after the di-
agnosis of breast cancer, and 16 patients (1.9%) had metachro-
nous MPCs ≥6 months both before and after the diagnosis of 
breast cancer. Synchronous MPCs were noted in 204 patients 
(23.8%), and metachronous MPCs were identified in 678 pa-
tients (79.0%). There were also 24 patients (2.8%) with both sy-
nchronous and metachronous MPCs. 
In the 858 patients with MPCs, a total of 962 primary malig-
nancies were detected. Second primary cancer alone was not-
ed in 762 patients (88.8%), and 96 patients (11.2%) had two or 
more primary malignancies other than breast cancer. Disease 
sites and numbers of cases are presented in Table 1. Cancers 
of the endocrine system, which mainly included the thyroid 
gland, were the most prevalent malignancy in Korean breast 
cancer patients, and more than two-thirds of synchronous 
MPCs were thyroid cancer. Subsequently, primary tumors of 
the gynecologic system including the ovary, cervix, and uterus 
were the second-most prevalent cancer. Interestingly, in pa-
tients with metachronous MPCs, primary cancers more frequ-
ently developed in respiratory and hematologic systems after, 
rather than before, the diagnosis of breast cancer. Fig. 1 shows 
the time intervals between breast cancer and MPCs. When ex-
cluding 53 metachronous cases (5.5%) that were diagnosed as 
MPCs before diagnosis of breast cancer and did not have in-
Table 1. Site and Number of Multiple Primary Cancers 
Site
Synchronous MPCs
(n=207, %)
Metachronous MPCs
Total
(n=962, %)
1st cancer is not breast 
cancer (n=323, %)
1st cancer is breast 
cancer (n=432, %)
Subtotal
(n=755, %)
Thyroid gland 147 (71.0) 96 (29.7) 162 (37.5) 258 (34.2) 405 (42.1)
Gynecologic system 20 (9.7) 90 (27.9) 70 (16.2) 160 (21.2) 180 (18.7)
Stomach & esophagus 9 (4.3) 34 (10.5) 39 (9.0) 73 (9.7) 82 (8.5)
Colon & rectum 4 (1.9) 31 (9.6) 31 (7.2) 62 (8.2) 66 (6.9)
Lung & thorax 4 (1.9) 11 (3.4) 30 (6.9) 41 (5.4) 45 (4.7)
Hepatobiliary & pancreas 8 (3.9) 16 (5.0) 33 (7.6) 49 (6.5) 57 (5.9)
Urologic system 2 (1.0) 10 (3.1) 13 (3.0) 23 (3.0) 25 (2.6)
Hematologic system 0 (0.0) 11 (3.4) 26 (6.0) 37 (4.9) 37 (3.8)
Nervous system 6 (2.9) 12 (3.7) 9 (2.1) 21 (2.8) 27 (2.8)
Bone & soft tissue 3 (1.4) 2 (0.6) 7 (1.6) 9 (1.2) 12 (1.2)
Other 4 (1.9) 10 (3.1) 12 (2.8) 22 (2.9) 26 (2.7)
MPCs, multiple primary cancers.
Fig. 1. Time interval between breast cancer and development of multiple primary cancers.
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formation available to identify the date of cancer diagnosis, 166 
cases (18.3%) had a past history of malignancy between 6 
months and 5 years before diagnosis of breast cancer, and 275 
cases (30.5%) developed MPCs between 6 months and 5 years 
after diagnosis of breast cancer.
Table 2 summarizes the clinicopathologic characteristics as-
sociated with breast cancer according to the presence or ab-
sence of MPCs and stratified by a cutoff follow-up duration of 
5 years. At ≤5 years, the mean age of patients with MPCs was 
52.7 years, which was significantly older than those with breast 
cancer alone. Patients with MPCs showed smaller tumor size, 
higher node-negative disease, and lower TNM staging at the 
time of diagnosis of breast cancer. ER, PR, and HER2 expres-
sions were not significantly different between groups. Similarly, 
Table 2. Clinicopathologic Characteristics Associated with Breast Cancer According to Follow-Up Duration of 5 Years
Time period ≤5 yrs Time period >5 yrs
Breast cancer alone 
(n=7478, %)
MPCs
(n=726, %)
p value
Breast cancer alone 
(n=3316, %)
MPCs
(n=429, %)
p value
Age at diagnosis of breast cancer (yrs, n=8204)
Mean±SD 48.9±10.6 52.7±10.7 <0.001* 47.4±9.8 50.3±9.8 <0.001*
≤50 4491 (60.1) 344 (47.4) <0.001 2182 (65.8) 220 (51.3) <0.001
>50 2987 (39.9) 382 (52.6) 1134 (34.2) 209 (48.7)
T stage (n=8135) <0.001 0.001
Tis-1 4683 (63.1) 510 (70.9) 1847 (56.2) 276 (64.8)
T2–4 2733 (36.9) 209 (29.1) 1439 (43.8) 150 (35.2)
N stage (n=8139) 0.030 0.893
N0 4904 (66.1) 504 (70.1) 2067 (62.9) 267 (62.5)
N1–3 2516 (33.9) 215 (29.9) 1221 (37.1) 160 (37.5)
TNM stage (n=8137) <0.001 0.053
Stage 0–1 3585 (48.3) 409 (56.9) 1382 (42.0) 205 (48.0)
Stage 2 2830 (38.2) 240 (33.4) 1419 (43.2) 161 (37.7)
Stage 3 1003 (13.5) 70 (9.7) 486 (14.8) 61 (14.3)
ER (n=7690) 0.796 0.244
Positive 4784 (68.4) 475 (68.0) 2010 (67.7) 255 (64.7)
Negative 2207 (31.6) 224 (32.0) 961 (32.3) 139 (35.3)
PR (n=7667) 0.097 0.316
Positive 4153 (59.6) 394 (56.4) 1851 (62.7) 236 (60.1)
Negative 2815 (40.4) 305 (43.6) 1103 (37.3) 157 (39.9)
HER2 (n=6107) 0.175 0.801
Positive 1407 (25.5) 137 (23.0) 564 (26.5) 76 (25.8)
Negative 4104 (74.5) 459 (77.0) 1568 (73.5) 219 (74.2)
MPCs, multiple primary cancers; SD, standard deviation; is, in situ; TNM, tumor node metastasis; ER, estrogen receptor; PR, progesterone receptor; HER2, hu-
man epidermal growth factor receptor 2.
*Student’s t-test.
Fig. 2. Overall survival curve of patients with and without MPCs (A) at ≤5 years and (B) at >5 years. MPCs, multiple primary cancers.
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at >5 years, patients with MPCs were older in age at diagnosis 
of breast cancer and showed smaller tumor sizes. However, 
node status was not significantly different between patients with 
and without MPCs; differences in TNM stage showed border-
line statistical significance.
During a mean follow-up duration of 67.3 months for the 
whole population, the OS of patients with and without MPCs 
are shown in Fig. 2. Although patients with MPCs demonstrat-
ed a higher proportion of stage 0–I disease, they also showed 
worse survival than the breast-cancer-alone group at both ≤5 
and >5 years. Table 3 shows causes of death. Of the 978 patients 
who died during this study, 53 (5.4%) did not have an identifi-
able cause of death, and most were in the breast-cancer-alone 
group. At ≤5 years, a significantly higher number of patients 
with MPCs died due to reasons not associated with breast can-
cer, and at >5 years, causes of death were similar to those at ≤5 
years.
When adjusting for age, TNM stage, and ER expression at di-
agnosis of breast cancer, patients with MPCs were significant-
ly associated with an increased risk of death at ≤5 years (Table 
4). However, a slightly increased risk of death in patients with 
MPCs did not reach statistical significance at >5 years. Older 
age, advanced TNM stage, and ER-positive disease were inde-
pendent prognostic factors at >5 years. A stage-matched sub-
group analysis showed that patients with MPCs had signifi-
cantly worse OS than the breast-cancer-alone group for stage 0–
I disease at both ≤5 and >5 years and for stage II disease at ≤5 
years (Fig. 3). Nevertheless, no statistical difference in OS was 
noted between stage II disease at >5 years and stage III disease 
irrespective of follow-up duration.
DISCUSSION
It is occasionally clinically difficult to distinguish new second 
primary malignancies from a metastatic neoplasm during the 
follow-up of cancer survivors. MPCs are generally considered 
new primary cancers when detected in a patient with a prior 
history of malignancy that is in a new site or tissue and subse-
quent to the initial cancer.5 Cancer survivors have a higher risk 
of developing MPCs than the general population, and studies 
using population-based registry datasets have demonstrated 
standardized incidence ratios for subsequent MPCs of 1.17 to 
1.6 in female cancer survivors.5,8,13,14 Recently, these relative 
risks for developing MPCs among women with breast cancer 
were reported differently, with ratios as high as 1.96 [95% confi-
Table 3. Survival and Cause of Death
Time period ≤5 yrs Time period >5 yrs
Breast cancer alone 
(n=7478, %)
MPCs (n=726, %) p value
Breast cancer alone 
(n=3316, %)
MPCs (n=429, %) p value
Survival <0.001 0.008
Alive 6991 (93.5) 645 (88.8) 2969 (89.5) 366 (85.3)
Dead 487 (6.5) 81 (11.2) 347 (10.5) 63 (14.7)
Cause of death <0.001 <0.001
Related to breast cancer 416 (87.2) 47 (58.0) 267 (87.3) 26 (42.6)
Not related to breast cancer 61 (12.8) 34 (42.0) 39 (12.7) 35 (57.4)
MPCs, multiple primary cancers.
Table 4. Multivariate Analysis for Overall Survival
Time period ≤5 yrs Time period >5 yrs
Hazard ratio 95% confidence interval p value Hazard ratio 95% confidence interval p value
Age at diagnosis of breast cancer (yrs)
≤50 Ref. Ref.
>50 1.125 0.944–1.339 0.187 1.556 1.263–1.916 <0.001
TNM stage
Stage 0–1 Ref. Ref.
Stage 2 2.663 2.060–3.444 <0.001 1.824 1.369–2.430 <0.001
Stage 3 9.271 7.205–11.930 <0.001 3.834 2.850–5.158 <0.001
ER
Positive Ref. Ref.
Negative 2.163 1.820–2.570 <0.001 0.779 0.621–0.976 0.030
Multiple primary cancers
Breast cancer alone Ref. Ref.
MPCs 1.927 1.505–2.468 <0.001 1.195 0.897–1.593 0.223
Ref., reference; TNM, tumor node metastasis; ER, estrogen receptor; MPCs, multiple primary cancers.
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dence interval (CI), 1.48–2.44] according to age at diagnosis of 
breast cancer.15,16 However, there has been no official study on 
MPCs from the nationwide Korean Central Cancer Registry.
In Korea, incidence rates of female thyroid cancer have in-
creased sharply since the early 2000s, and this was found to be 
the most common malignancy of Korean women, with an age-
standardized incidence rate of 87.4 in 2010.3 In our study, thy-
roid cancer was the most prevalent malignancy among breast 
cancer patients. Interestingly, more than two-thirds of patients 
with synchronous MPCs had a thyroid malignancy with breast 
cancer. Globally, incidence rates of thyroid cancer have in-
creased, with the exception of countries such as Sweden, Nor-
way, and Spain. The cause of such changing trends in the inci-
dence of thyroid cancer may be multifactorial, although it re-
mains unclear.17 It also remains to be determined whether our 
results reflect a true increase in the development of Korean thy-
roid cancer, an increased identification of previously undetect-
able subclinical thyroid disease along with improved diagnos-
tic techniques and screening rates, or close biological connec-
tions between female breast and thyroid cancers.3,18
Fig. 3. Stage-matched overall survival curve (A, B, and C) at ≤5 years and (D, E, and F) at >5 years. (A and D) Stage 0–I; (B and E) stage II; and (C and F) 
stage III disease. The dotted line represents patients with breast cancer alone, and the solid line indicates patients with multiple primary cancers.
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It has been suggested that certain types of anticancer treat-
ments are closely linked to an increased risk of developing MPCs 
in cancer survivors.19-21 Examples include findings that cytotox-
ic chemotherapy was associated with an increased risk for leu-
kemia, chest irradiation for Hodgkin’s disease was related to 
an increased risk of breast cancer, and tamoxifen treatment for 
breast cancer was connected to a higher risk of endometrial 
cancer.15,18,20,22 By analyzing patients with MPCs among our 
study cohort, the proportions of patients with malignancy in 
the thyroid gland, lung, thorax, and hematologic system were 
elevated after, rather than before, the diagnosis and treatment of 
breast cancer. In this study, we were unable to confirm wheth-
er certain types of cancer were developed in association with 
anticancer therapies, and in the future, it will be necessary to 
further investigate this topic. In addition, given that MPCs in 
the gynecologic system were the second-most common ma-
lignancy and development of breast and ovarian cancer shares 
a close genetic linkage in deleterious BRCA 1 & 2 mutation car-
riers, results of the Korean Hereditary Breast Cancer (KOH-
BRA) Study for the Korean population may shed further light on 
this topic.23
In the present study, patients with MPCs showed a higher 
proportion of early-stage breast cancer, especially at ≤5 years. 
Recent meta-analyses suggested that cancer survivors were 
more likely to be screened for breast, cervical, colorectal, and 
prostate cancer than non-cancer controls.24,25 Cross-sectional 
surveys involving the Korean population have shown that sc-
reening rates for breast cancer within 2 years were 46.4% (95% 
CI, 36.2–56.7) in cancer survivors, 36.0% (95% CI, 33.2–38.9) in 
non-cancer chronic disease controls, and 30.0% (95% CI, 27.8–
32.2) in non-cancer non-chronic disease controls when adjust-
ed for gender, age, marital status, education, income, working 
status, insurance status, smoking and drinking status, self-re-
ported health status, and survey year.26 Higher screening rates 
and interest in personal health among patients with metachro-
nous MPCs could partly explain our results; however, further 
investigation of the association of health screening with the first 
primary cancer and subsequent MPCs is required.
There have been limited data regarding the impact of MPCs 
on the survival of breast cancer patients. One early study of Ko-
rean breast cancer patients reported no difference in survival 
according to MPCs.10 However, in a recent study by the M.D. 
Anderson Cancer Center on 4198 patients treated with breast 
conservation therapy, patients with MPCs showed a worse OS 
than those without MPCs after excluding patients who had a 
past history of malignancy prior to the diagnosis of breast can-
cer.27 Similarly, patients with MPCs in this study demonstrated 
a worse survival than those without MPCs, and most died due 
to diseases other than breast cancer. Although statistical sig-
nificance in the multivariate analysis was not maintained at >5 
years as more than half of the patients were lost to follow-up, 
further long-term study is needed. Stage-matched subgroup 
analysis revealed that the implications of MPCs on breast can-
cer survival were more significantly evident among patients 
with early stage 0–I disease, yet not among those with advanced 
stage II–III disease.
Many cancer survivors do not perceive their risk of a subse-
quent second primary malignancy, and appropriate screening 
rates among Korean cancer survivors are suboptimal com-
pared to the United States.5 Therefore, awareness and educa-
tion regarding the development of MPCs and importance of 
screening programs are required for both cancer survivors and 
surgical and medical oncologists.28,29 In addition, as there are 
no evidence-based guidelines on screening programs for can-
cer survivors, it is accepted that cancer survivors should, at 
minimum, follow the screening guidelines for the general pop-
ulation until the establishment of screening guidelines for can-
cer survivors. Limitations of the present study include the ret-
rospective nature of the survival analysis over a short duration 
of follow-up and the use of a hospital-based registry database 
at a single institution. More importantly, it was not possible to 
incorporate details of TNM stage, treatment patterns of MPCs, 
or environmental risk factors in the analysis.
In conclusion, Korean breast cancer patients are at a risk of 
second or multiple primary malignancies. Cancers most com-
monly occurred in the thyroid gland and gynecologic system. 
Breast cancer patients with MPCs exhibited worse survival, and 
many died due to causes unrelated to breast cancer. However, 
these patients were older at diagnosis and had lower breast 
cancer staging. The implications of MPCs on survival were 
more evident when patients had early-stage breast disease. Th-
erefore, further efforts are needed to investigate the nation-
wide incidence of MPCs in order to discover the causes of in-
creased risk for MPCs, to develop preventive methods for MPCs, 
and to increase awareness of and enrollment in screening 
programs for breast cancer survivors.
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